Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cell Genesys
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years or older
Suspicious diagnosis of or histologically- confirmed stage IIIB or IV non small-cell lung cancer
Accessible and adequate tumor source for vaccine production.
Tumor source for vaccine production must be accessible by a minor surgical procedure performed under local or regional anesthesia (e.g. lymph node or soft tissue mass or malignant pleural effusion)
Measurable disease to evaluate following tumor procurement
Limited metastatic tumor burden
Life expectancy at least 4 months
ECOG Performance Status 0 - 1
You may not be if
Active and/or untreated brain metastases
Active or impending spinal cord compression
Active auto-immune disease or treatment with immunosuppressants
Decompensated congestive heart failure or recent significant cardiac event
Coexisting malignancies
Significant or uncontrolled medical problems or laboratory abnormalities that might increase the risk of surgical complications or vaccine treatment
Previous treatment with gene therapy (including any adenoviral-based therapy)
Clareo Health | A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)
